Prophylactic Antibiotic Use in Hernioplasty
Information source: Nihon Univerity
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Inguinal Hernia
Intervention: Antibiotic: cefazolin Sodium (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Nihon Univerity Overall contact:
Takero Mazaki, MD, PhD, Phone: 81339793611, Ext: 8112, Email: tmazaki@med.nihon-u.ac.jp
Summary
The purpose of this study is to determine whether prophylactic antibiotic use in inguinal
hernioplasty are effective in prevention of infectious complication.
Clinical Details
Official title: Prophylactic Antibiotic Use in Inguinal Hernioplasty: A Placebo-Controlled, Double-Blind Trial
Study design: Prevention, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: infectious complication
Secondary outcome: Recurrence of inguinal hernia
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Primary inguinal hernia
- Elective surgery
- Must be older than 20 years of age
- Must not have any serious complication
Exclusion Criteria:
- Incarceration
- Recurrence
- Drug allergy
- Diabetes mellitus
- Malignant diseases
- Serious heart diseases
- Psychological diseases
- Pregnancy
- Have been medicated with corticosteroids
Locations and Contacts
Takero Mazaki, MD, PhD, Phone: 81339793611, Ext: 8112, Email: tmazaki@med.nihon-u.ac.jp
Nihon University School of Medicine, Department of Surgery, Tokyo 179-0072, Japan; Recruiting
Takero Mazaki, MD, PhD, Principal Investigator
Additional Information
Starting date: July 2007
Ending date: December 2009
Last updated: March 10, 2008
|
